Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.0354
Abstract: Importance De novo bullous pemphigoid (BP) is a rare immune-mediated adverse event from immune checkpoint inhibitors (ICIs) that can necessitate permanent discontinuation of the anticancer therapy, but the risk factors for developing this toxic effect… read more here.
Keywords: bullous pemphigoid; immune checkpoint; ici; risk factors ... See more keywords
Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2021.0249
Abstract: Importance Encephalitis is a severe immune-related adverse event secondary to treatment with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) ranges from disease that resolves fully to lethal forms. Moreover, ICIs may unmask… read more here.
Keywords: immune checkpoint; checkpoint inhibitors; ici; prognosis ... See more keywords
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.3707
Abstract: Importance Approval by the US Food and Drug Administration of immune checkpoint inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status has generated controversy. Exploratory analyses from individual trials indicate a lack of… read more here.
Keywords: immune checkpoint; expression; ici; analysis ... See more keywords
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5939
Abstract: BACKGROUND It is still unclear whether patients with advanced non-small cell lung cancer (NSCLC), with disease progression after initial immune checkpoint inhibitor (ICI) therapy, would benefit from ICIs readministration. PATIENTS AND METHODS We retrospectively collected… read more here.
Keywords: ici; group; ici retreatment; disease progression ... See more keywords
How Can Urodynamic Innovations be Better Integrated Into the Clinical Pathway?: ICI-RS 2025.
Sign Up to like & getrecommendations! Published in 2025 at "Neurourology and urodynamics"
DOI: 10.1002/nau.70176
Abstract: BACKGROUND Urodynamics has seen, in common with any medical field reliant upon technology, many recent advances in the application of innovations. Novel and effective ideas have been developed and marketed, but relatively few have been… read more here.
Keywords: better integrated; integrated clinical; innovations better; urodynamic innovations ... See more keywords
The Integrated Calibration Index (ICI) and related metrics for quantifying the calibration of logistic regression models
Sign Up to like & getrecommendations! Published in 2019 at "Statistics in Medicine"
DOI: 10.1002/sim.8281
Abstract: Assessing the calibration of methods for estimating the probability of the occurrence of a binary outcome is an important aspect of validating the performance of risk‐prediction algorithms. Calibration commonly refers to the agreement between predicted… read more here.
Keywords: index; regression; ici; integrated calibration ... See more keywords
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-024-05713-6
Abstract: Adjuvant treatment with immune checkpoint inhibitors, such as PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT), has shown a significant improvement in disease-free survival (DFS) for high-risk melanoma patients. However, due to specific… read more here.
Keywords: treatment; melanoma; toxicity; side effects ... See more keywords
Cardiotoxicity of Immune Checkpoint Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology Reports"
DOI: 10.1007/s11912-021-01070-6
Abstract: Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression,… read more here.
Keywords: immune checkpoint; risk; checkpoint inhibitors; ici ... See more keywords
Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina.
Sign Up to like & getrecommendations! Published in 2021 at "Chest"
DOI: 10.1016/j.chest.2021.02.032
Abstract: BACKGROUND Immune checkpoint inhibitors (ICI) are standard treatments for advanced non-small cell lung cancer and have expanded use in small cell lung cancer. While generally better tolerated than traditional chemotherapy, immune-related adverse events, such as… read more here.
Keywords: ici; risk factors; lung; lung cancer ... See more keywords
Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.03.004
Abstract: AIMS The activity that the immune checkpoint inhibitor (ICI) cemiplimab has recently demonstrated has led to a paradigm shift in the management of patients with advanced cutaneous squamous cell carcinoma (cSCC). To identify predictive biomarkers… read more here.
Keywords: ici; response; cell carcinoma; squamous cell ... See more keywords
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.01.036
Abstract: INTRODUCTION Immune checkpoint inhibitors (ICIs) have proved to be an effective treatment for up to 40% of muscle-invasive bladder cancer (MIBC), but there is still a need for better performing biomarkers allowing to improve prediction… read more here.
Keywords: bladder cancer; ici; response; tls ... See more keywords